» Articles » PMID: 23908927

A Community-based Sero-epidemiological Study of Hepatitis B Infection in Lianyungang, China, 2010

Overview
Date 2013 Aug 3
PMID 23908927
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The 2010 targets of the China Hepatitis B Prevention Programme were a prevalence of hepatitis B surface antigen (HBsAg) less than 1.0% for children less than five years old and less than 6.0% for the total population. This survey assessed the prevalence of Hepatitis B infection in Lianyungang, Jiangsu province, China in 2009-2010.

Methods: Multistage sampling was used with 2372 subjects among 17 selected villages. Blood specimen collection and testing by enzyme-linked immunosorbnet assay (ELISA) were completed using the following markers for hepatitis infection: HBsAg and antibody to HBsAg (anti-HBs); hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe); and hepatitis B core antibody (total anti-HBc). The data were analysed with Epi Info, version 3.3.2.

Results: The prevalence of HBsAg was 2.4% (95% Confidence Interval [CI]: 1.8-3.0; Adjusted Prevalence [AP] 2.9%); anti-HBs prevalence was 51.1% (95% CI: 49.1-53.1; AP 49.2%) and total anti-HBc prevalence was 41.7% (95% CI: 39.8-43.7; AP 45.5%). The prevalence of HBsAg and total anti-HBc positivity increased from young to older age groups, yet the prevalence of anti-HBs positivity decreased from young to older age groups (P < 0.001 for all). There was no difference in the prevalences of HBsAg and anti-HBs among females and males (P = 0.108 and 0.089), but females had a higher prevalence than males for total anti-HBc positivity (P < 0.001).

Discussion: This survey showed that in 2010 the prevalence of HBsAg among children aged less than five years was lower than the national target of 1.0% and that the prevalence of HBsAg for the total population was lower than the national target of 6.0%.

Citing Articles

Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt.

Salama I, Sami S, Elserougy S, Emam H, Salama S, Elhariri H Oman Med J. 2020; 35(5):e175.

PMID: 33083033 PMC: 7538637. DOI: 10.5001/omj.2020.117.


Protection Provided by Hepatitis B Vaccine in Adult Population of Chaharmahal and Bakhtiari Province, Iran in 2013.

Moezzi M, Imani R J Clin Diagn Res. 2016; 10(4):LC01-4.

PMID: 27190834 PMC: 4866132. DOI: 10.7860/JCDR/2016/17758.7548.


Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Mori S, Fujiyama S World J Gastroenterol. 2015; 21(36):10274-89.

PMID: 26420955 PMC: 4579875. DOI: 10.3748/wjg.v21.i36.10274.


Hepatitis B seroprevalence and risk factors in adult population of chaharmahal and bakhtiari province in 2013.

Moezzi M, Imani R, Khosravi N, Pourheidar B, Ganji F, Karimi A Hepat Mon. 2014; 14(5):e17398.

PMID: 24910705 PMC: 4030265. DOI: 10.5812/hepatmon.17389.

References
1.
Liang X, Chen Y, Wang X, He X, Chen L, Wang J . [A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old]. Zhonghua Liu Xing Bing Xue Za Zhi. 2006; 26(9):655-8. View

2.
Liang X, Bi S, Yang W, Wang L, Cui G, Cui F . Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27(47):6550-7. DOI: 10.1016/j.vaccine.2009.08.048. View

3.
Cui F, Bi S, Zhang Y . [Combination profiles of hepatitis B marks for Chinese in serosurvey in 2006]. Zhongguo Yi Miao He Mian Yi. 2010; 15(4):294-9. View